Literature DB >> 20485179

The effects of protamine overdose on coagulation parameters as measured by the thrombelastograph.

Nouman U Khan1, Charlotte K Wayne, Julian Barker, Timothy Strang.   

Abstract

BACKGROUND AND
OBJECTIVE: Protamine is routinely administered following cardiopulmonary bypass in order to neutralize the effects of heparin. An excess of protamine can contribute to coagulopathy, hence predisposing to bleeding with associated morbidity and mortality. Thromboelastography (TEG) is recognized as an invaluable bedside tool to detect coagulation parameters; however, the effects of protamine overdose on TEG parameters have not been fully established.
METHODS: Forty-six patients undergoing cardiac surgery using cardiopulmonary bypass were recruited in the study. Following heparinization, the patient's blood heparin level was measured using Hepcon HMS. Incremental doses of protamine [at a protamine-to-Hepcon-derived heparin ratio (PHR) of 1:1, 2:1 and 3:1] were added to patients' blood samples in vitro and four TEG coagulation parameters, including R (time to clot initiation), K (clot kinetics), alpha (clot kinetics) and maximum amplitude (ultimate clot strength), were monitored. Statistical analysis was performed using NCSS software.
RESULTS: Protamine caused dose-dependent worsening of coagulation parameters on TEG; K was significantly elevated, whereas alpha and maximum amplitude showed significant reduction (P < 0.001) compared with baseline at a PHR of 2:1 and 3:1, respectively. R was significantly prolonged compared with baseline (P < 0.001) at a PHR of 3:1.
CONCLUSION: Protamine adversely affects clot initiation time, clot kinetics and platelet function in a dose-dependent manner, which can predispose to bleeding.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20485179     DOI: 10.1097/EJA.0b013e32833731bd

Source DB:  PubMed          Journal:  Eur J Anaesthesiol        ISSN: 0265-0215            Impact factor:   4.330


  11 in total

Review 1.  Paradoxical and bidirectional drug effects.

Authors:  Silas W Smith; Manfred Hauben; Jeffrey K Aronson
Journal:  Drug Saf       Date:  2012-03-01       Impact factor: 5.606

2.  Method to calculate the protamine dose necessary for reversal of heparin as a function of activated clotting time in patients undergoing cardiac surgery.

Authors:  Javier Suárez Cuenca; Pilar Gayoso Diz; Francisco Gude Sampedro; J Marcos Gómez Zincke; Helena Rey Acuña; M Manuela Fontanillo Fontanillo
Journal:  J Extra Corpor Technol       Date:  2013-12

3.  Alteration of blood clotting and lung damage by protamine are avoided using the heparin and polyphosphate inhibitor UHRA.

Authors:  Manu Thomas Kalathottukaren; Libin Abraham; Piyushkumar R Kapopara; Benjamin F L Lai; Rajesh A Shenoi; Federico I Rosell; Edward M Conway; Edward L G Pryzdial; James H Morrissey; Charles A Haynes; Jayachandran N Kizhakkedathu
Journal:  Blood       Date:  2016-12-29       Impact factor: 22.113

4.  Impact of aspirin on bleeding and blood product usage in off-pump and on-pump coronary artery bypass graft surgery.

Authors:  Christopher Little; Zain Odho; Richard Szydlo; Tuan-Chen Aw; Mike Laffan; Deepa R J Arachchillage
Journal:  EJHaem       Date:  2022-02-16

5.  Updates on coagulation management in cardiac surgery.

Authors:  Mahdi Najafi; David Faraoni
Journal:  J Tehran Heart Cent       Date:  2014

6.  The Inhibitory Effect of Protamine on Platelets is Attenuated by Heparin without Inducing Thrombocytopenia in Rodents.

Authors:  Joanna Miklosz; Bartlomiej Kalaska; Kamil Kaminski; Malgorzata Rusak; Krzysztof Szczubialka; Maria Nowakowska; Dariusz Pawlak; Andrzej Mogielnicki
Journal:  Mar Drugs       Date:  2019-09-17       Impact factor: 5.118

7.  Impact of different dosage of protamine on heparin reversal during off-pump coronary artery bypass: a clinical study.

Authors:  Salvatore Suelzu; Andrea Cossu; Giovanni Pala; Michele Portoghese; Valeria Columbanu; Gabriele Sales; Luigi Solinas; Luca Brazzi
Journal:  Heart Lung Vessel       Date:  2015

8.  The effects on coagulation of the reinfusion of unprocessed residual blood from the cardiopulmonary bypass.

Authors:  Yolande-Leigh Iyer; Philip Hayward; Larry McNicol; Laurence Weinberg
Journal:  BMC Res Notes       Date:  2016-02-03

9.  Is There a "Blind Spot" in Point-of-Care Testing for Residual Heparin After Cardiopulmonary Bypass? A Prospective, Observational Cohort Study.

Authors:  Saskia Wand; Daniel Heise; Nadine Hillmann; Christian Bireta; Anselm Bräuer; Nicolas von Ahsen; Michael Quintel
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

10.  Heparin reversal by an oligoethylene glycol functionalized guanidinocalixarene.

Authors:  Qiaoxian Huang; Hong Zhao; Mingju Shui; Dong-Sheng Guo; Ruibing Wang
Journal:  Chem Sci       Date:  2020-08-28       Impact factor: 9.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.